- 最后登录
- 2011-1-10
- 在线时间
- 5 小时
- 寄托币
- 79
- 声望
- 0
- 注册时间
- 2010-7-27
- 阅读权限
- 15
- 帖子
- 0
- 精华
- 0
- 积分
- 51
- UID
- 2864795

- 声望
- 0
- 寄托币
- 79
- 注册时间
- 2010-7-27
- 精华
- 0
- 帖子
- 0
|
发表于 2010-7-30 23:50:50
|显示全部楼层
第一次写作文,随便捡了一篇连翻书带查字典的,写了一个多小时。。。
大家帮忙改改~~:loveliness:
Argument 5
The following appeared in the business section of a newspaper.
"Given that the number of people in our country with some form of arthritis is expected to rise from 40 million to 60 million over the next twenty years, pharmaceutical companies that produce drugs for the treatment of arthritis should be very profitable. Many analysts believe that in ten years Becton Pharmaceuticals, which makes Xenon, the best-selling drug treatment for arthritis, will be the most profitable pharmaceutical company. But the patent on Xenon expires in three years, and other companies will then be able be produce a cheaper version of the drug. Thus, it is more likely that in ten years the most profitable pharmaceutical company will be Perkins Pharmaceuticals, maker of a new drug called Xylan, which clinical studies show is preferred over Xenon by seven out of ten patients suffering from the most extreme cases of arthritis."
我的提纲:
1、没有直接证据说明Xylan赚钱
2、BP不一定会赚的少
3、未来几年完全可能出现新的公司新的技术
The author claims that in ten years the most profitable pharmaceutical company will be Perkins Pharmaceuticals (PP) which makes Xylan (XY) rather than Becton Pharmaceuticals (BP) which makes Xenon (X). However, the author's argument is problematic in several respects, rending the argument unconvincing as it stands.
First of all, there is no direct evidence indicating that XY can make profit. The clinical studies can only explain XY is effective but not illustrate people are willing to use it. Besides, given that XY is more useful in most extreme cases, it is entirely possible that X is more useful than XY in normal cases which most of the patients suffer from. If it comes to that, then X will still be wide used. Lacking the evidence that XY will be popular, it is difficult to assess XY can bring profit.
Secondly, even if XY will beat X, one cannot infer that the profit of BP will decrease. BP also can make new drugs, then it probably continue to dominate the market. And even if the patent gone, BP can lower price, other companies’ do not necessarily cheaper than its. There is also a possibility that consumers feel more at ease using BP's products though they are higher in price. Without eliminating these possibilities, the author cannot conclude that PP will be more profitable.
Finally, the author fails to take into account that there may be new companies and new technologies in the next few years. Technologies developed rapidly in today’s world, perhaps a more effective new drug will be made to treat arthritis. Besides, if pharmaceutical companies earn much money, other companies also will make investment. By that time, BP and PP may both fell behind resulting in the most profitable is neither BP nor PP.
In conclusion, the author assumes hastily that PP will be the most profitable among pharmaceutical companies in ten years. To strengthen it the author should conduct a survey to indicate XY will be popular. I would also need to know more information of BP and other companies. |
|